PDT Partners LLC purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the third quarter, Holdings Channel.com reports. The firm purchased 11,701 shares of the company’s stock, valued at approximately $1,052,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics in the 2nd quarter worth about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Axsome Therapeutics in the second quarter worth approximately $47,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after buying an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new position in Axsome Therapeutics during the third quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. acquired a new stake in Axsome Therapeutics in the third quarter valued at approximately $236,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. This represents a 52.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 22.40% of the stock is owned by company insiders.
Axsome Therapeutics Stock Performance
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same quarter in the prior year, the firm posted ($1.32) EPS. Equities research analysts anticipate that Axsome Therapeutics, Inc. will post -4.58 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms have recently weighed in on AXSM. HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of Axsome Therapeutics in a report on Monday, November 25th. Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $95.00 to $106.00 in a research report on Tuesday, August 6th. Robert W. Baird raised their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Royal Bank of Canada upped their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $130.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $124.93.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
- Five stocks we like better than Axsome Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Comparing and Trading High PE Ratio Stocks
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- The 3 Best Fintech Stocks to Buy Now
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.